ClinicalTrials.gg
RecruitingNCT06682442Updated Jun 17, 2026

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

An interventional study of Intensity-Modulated Radiation Therapy (IMRT) and Radiographic Imaging in Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8 and Stage IVA Nasopharyngeal Carcinoma AJCC v8, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Nasopharyngeal Carcinoma with a site in United States — 16 open to participants now, 26 under way, 3 of them phase 3. Nasopharyngeal Carcinoma · United States.

Planned enrollment
27th of 57
66 · median 50
Started
2025
with 4 others
No phase
4 of 59
3 open now
Primary completion
2029-05
later than 22 of 25 live
Registered
54th of 59
by date

Among the 59 studies in Nasopharyngeal Carcinoma with a site in United States, this one is the 27th largest by planned enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 with no phase, reaches primary completion later than 22 of the 25 other live ones, and was the 54th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

16 of the 59 studies in Nasopharyngeal Carcinoma with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Nasopharyngeal Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy [IMRT]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is an advanced form of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Radiation therapy sometimes causes unwanted symptoms or side effects, including late effects such as hearing loss and dental problems. The severity of the side effects is related to the radiation dose received and the amount of tissue that received radiation. De-escalation IMRT uses lower doses of radiation based on a good response to induction chemotherapy. Giving de-escalated IMRT may be as effective as standard doses of IMRT in treating patients with EBV-associated nasopharyngeal cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To measure the proportion of participants alive without progression of disease two years following induction therapy (IT) response-guided IMRT.

SECONDARY OBJECTIVES:

I. To assess the 1-year rate of progression-free survival (PFS) after IT response-guided IMRT.

II. To assess the 1- and 2-year cumulative incidence of locoregional recurrence (LRR) after IT response-guided IMRT.

III. To assess the 1- and 2-year cumulative incidence of distant metastasis (DM) after IT response-guided IMRT.

IV. To assess the 1- and 2-year rates of overall survival (OS) after IT response-guided IMRT.

V. To compare the rates of severe acute toxicities between standard and de-escalated IMRT.

VI. To compare the rates of severe late toxicities between standard and response-guided IMRT over a period of 2 years.

EXPLORATORY OBJECTIVES:

I. To compare the frequency of radiation treatment breaks between standard and de-escalated IMRT.

II. To compare the frequency of hospitalizations between standard and de-escalated IMRT.

III. To compare pre-treatment and short- and long-term post-treatment quality of life (QoL) after standard versus de-escalated IMRT.

IV. To compare pre-treatment and short- and long-term post-treatment levels of fatigue after standard versus de-escalated IMRT.

V. To compare radiation dosimetric parameters between standard and de-escalated IMRT.

VI. To explore differences in efficacy endpoints by sex, age, English language status, and race/ethnicity.

VII. To explore heterogeneity of treatment effects (HTEs) of efficacy endpoints by variables, such as sex, age, English language status, and race/ethnicity.

VIII. To explore the association between EBV deoxyribonucleic acid (DNA) levels and disease response on imaging upon completion of IT.

IX. To explore longitudinal EBV DNA levels after completion of IT response-guided IMRT.

X. To compare the rates of severe very late toxicities (from years 2 to 10 after completion of IMRT) between standard and response-guided IMRT.

XI. To explore the association between adjuvant (post-chemoradiation) systemic therapy use and oncologic outcomes (PFS, locoregional recurrence, distant metastasis, and overall survival), quality of life, and fatigue.

XII. To assess frequency of intra-treatment tumor hypoxia in participants undergoing standard and de-escalated radiotherapy.

XII. To explore the association between the presence of intra-treatment tumor hypoxia and baseline demographic and clinical characteristics.

XIV. To explore the association between the presence of intra-treatment tumor hypoxia and oncologic outcomes, toxicity, quality of life, and fatigue.

XV. To evaluate the relationship between intra-treatment tumor hypoxia and pre-treatment EBV DNA levels.

XVI. To evaluate the relationship between intra-treatment tumor hypoxia and end-of-treatment EBV DNA levels.

OUTLINE: Patients with partial radiographic response to IT in the primary tumor and lymph nodes are assigned to Arm I. Patients with stable or progressive disease are assigned to Arm II.

ARM I (DE-ESCALATED INTENSITY): Patients undergo de-escalated IMRT once daily (QD) 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT)/magnetic resonance imaging (MRI), positron emission tomography (PET), PET/CT, CT, and/or bone scans throughout the trial

ARM II (STANDARD): Patients undergo standard IMRT QD on 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/MRI, PET, PET/CT, CT, and/or bone scans throughout the trial.

After completion of study treatment, patients are followed up at 3 months then every 6 months for up to 10 years.

03

Conditions studied

  • Nasopharyngeal Carcinoma
  • Stage III Nasopharyngeal Carcinoma AJCC v8
  • Stage IVA Nasopharyngeal Carcinoma AJCC v8
  • Nasopharyngeal Cancer
  • Nasopharyngeal Cancer Stage

Keywords

  • HHV-4 Positive
  • EBV Positive
  • human herpesvirus 4 (HHV-4) positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed (from primary lesion and/or lymph nodes) nasopharyngeal carcinoma.
  • Participants must have Epstein Barr virus (EBV)-associated nasopharyngeal carcinoma, defined as detectable (> 0 copies/mL) circulating plasma EBV DNA on a qualitative or quantitative polymerase chain reaction (PCR)-based test.
  • Stage III-IVA disease (American Joint Committee on Cancer [AJCC], 8th edition [ed.]) with no evidence of distant at the time of diagnosis based upon all 3 of the following minimum diagnostic workup criteria:

    • History/physical examination by a medical oncologist or clinical oncologist or radiation oncologist or otolaryngology (ENT);
    • Evaluation of tumor extent with either one of the following:

      • MRI with contrast of the face, nasopharynx, and neck or CT with contrast of the face, nasopharynx and neck with ≤ 3 mm contiguous slices and bone windows to evaluate base of skull involvement; or
      • MRI of the nasopharynx and PET/CT (with contrast) of the neck
    • Imaging to rule out distant metastasis:

      • CT scan with contrast of the chest and abdomen (required) and the pelvis (optional) or a total body PET/CT scan (non-contrast PET/CT is acceptable); and
      • Only if clinically indicated: Bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
  • Started or planning to start platinum-based induction systemic therapy.
  • Planning to receive intensity modulated radiation therapy (IMRT) with concurrent, platinum-based systemic therapy during radiation.
  • Use of (post-chemoradiation) immunotherapy is permitted.
  • Age >=18 years.
  • (ECOG) performance status ≤ 2 ( ≥ 50%).
  • (HIV)-infected individuals on effective anti-retroviral therapy are eligible for this trial.
  • For individuals with evidence of chronic virus (HBV) infection: must be on suppressive therapy, if indicated.
  • For individuals with a history of virus (HCV) infection: must be currently on treatment, or must have been treated and cured.
  • Individuals with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Because the radiation therapy used in this trial is known to be teratogenic, individuals of must agree to use adequate (e.g., hormonal or barrier methods, abstinence) for the duration of study participation and for at least 60 days after the last administration of radiation therapy. Should a study participant or their partner become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic chemotherapy for nasopharyngeal carcinoma, other than induction chemotherapy (IT); note that prior chemotherapy for a different cancer is permitted
  • Prior radiotherapy to the nasopharynx or surrounding involved areas that would result in overlap of radiation therapy fields
  • Has participated in a study of an product and received treatment with an investigational drug or used an investigational device within 4 weeks prior to the first dose of treatment
  • Severe, active comorbidity, defined as any of the following:

    • Major medical or psychiatric illness that, in the treating investigator's opinion, would interfere with the completion of therapy and follow-up or interfere with a full understanding of the risks and potential complications of the therapy
    • Unstable angina, congestive heart failure, or peripheral vascular disease requiring hospitalization within the last 12 months; or other cardiac compromise that in the judgment of the treating investigator will preclude safe administration of study treatment
    • (COPD) exacerbation or other respiratory illness requiring hospitalization within 30 days prior to registration, or which would preclude safe administration study therapy in the opinion of the treating investigator
    • Active, untreated infection and/or acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Because the radiation therapy used in this trial is known to be teratogenic, individuals of must have documentation in their medical record of a negative pregnancy test

    * A female participant is considered to NOT be of child-bearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if the participant meets either of the following two criteria:

    • Has reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause)
    • Has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries)
  • Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study activities or interfere with participant safety or study endpoints
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Arm I (de-escalated Intensity Modulated Radiation Therapy (IMRT)

    Participants undergo de-escalated IMRT every day (QD) 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, MRI, PET, PET/CT, CT, and/or bone scans as well as providing blood samples throughout the trial.

    Radiation: Intensity-Modulated Radiation Therapy (IMRT) · Procedure: Radiographic Imaging · Procedure: Biospecimen Collection

  • Experimental
    Arm II (standard IMRT)

    Patients undergo standard IMRT QD 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, MRI, PET, PET/CT, CT, and/or bone scans as well as providing blood samples throughout the trial.

    Radiation: Intensity-Modulated Radiation Therapy (IMRT) · Procedure: Radiographic Imaging · Procedure: Biospecimen Collection

Interventions

  • RadiationIntensity-Modulated Radiation Therapy (IMRT)

    Undergo IMRT

    Also known as: IMRT, Intensity Modulated RT

  • ProcedureRadiographic Imaging

    Undergo imaging procedure

    Also known as: PET Scan, Positron Emission Tomography (PET), Computed Tomography (CT), CT, Magnetic Resonance Imaging (MRI), MRI, PET MRI, PET CT

  • ProcedureBiospecimen Collection

    Blood samples will be collected

    Also known as: Blood Specimen, Blood Sample

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival Rate (PFS) at 2 years post radiation

    PFS is defined as the proportion of participants alive without progression of disease from the first day of radiotherapy to progression or death by any cause, whichever occurs first, assessed up to 2 years after the last day of radiation therapy. The Kaplan-Meier method will be used to estimate the PFS rate along with a 90% confidence interval.

    Time frame: Up to 26 months

Secondary outcomes

  1. Progression-Free Survival Rate (PFS) at 1 year post radiation

    PFS is defined as the proportion of participants alive without progression of disease from the first day of radiotherapy to progression or death by any cause, whichever occurs first, assessed up to 1 year after the last day of radiation therapy. The Kaplan-Meier method will be used to estimate the PFS rate along with a 90% confidence interval.

    Time frame: Up to 14 months

  2. Locoregional recurrence rate (LRR) at 1 year post radiation

    LRR will be estimated using cumulative incidence from the first day of radiation to 1 year after the last day of radiation.

    Time frame: Up to 14 months

  3. Locoregional recurrence rate (LRR) at 2 years post radiation

    LRR will be estimated using cumulative incidence from the first day of radiation to 2 years after the last day of radiation.

    Time frame: Up to 26 months

  4. Incidence of Distant metastasis (DM) at 1 year post radiation

    DM will be estimated using cumulative incidence from the first day of radiation to 1 year after the last day of radiation.

    Time frame: Up to 14 months

  5. Incidence of Distant metastasis (DM) at 2 years post radiation

    DM will be estimated using cumulative incidence from the first day of radiation to 2 years after the last day of radiation.

    Time frame: Up to 26 months

  6. Median Overall Survival (OS) at 1 year post radiation

    Kaplan-Meier will be used to estimate OS

    Time frame: Up to 14 months

  7. Median Overall Survival (OS) at 2 years post radiation

    Kaplan-Meier will be used to estimate OS

    Time frame: Up to 26 months

  8. Overall Proportion of patients with grade ≥ 3 adverse events (AEs)

    Adverse Events will be reported from the start of radiation until 3 months after completion of radiation and will be graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. The percent of participants will be reported overall.

    Time frame: Up to 5 months

  9. Proportion of patients with acute grade ≥ 3 adverse events (AEs) by group

    Any adverse events from the start of radiation until 3 months after completion of radiation with a grade 3 or higher as determined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 will be reported as a percentage of the total participants for each treatment group.

    Time frame: Up to 5 months

  10. Proportion of patients with late onset grade ≥ 3 AEs by group post radiation

    Any adverse events from 3 months after completion radiation until 2 years after completion of radiation, with a grade 3 or higher as determined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 will be reported as a percentage of the total participants for each treatment group.

    Time frame: Up to 21 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2029, 50 months after the start.

Of 49 interventional studies with no phase under Nasopharyngeal Carcinoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Mar 18, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
Mar 31, 2032
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06682442
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Mar 18, 2025
Primary completion
May 31, 2029 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Jun 17, 2026

Study contacts

Imani Dunn
Contact
Imani.Dunn@ucsf.edu
877-827-3222
Sue Yom, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion